Abetimus sodium (LJP 394) ( DrugBank: Abetimus )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	3

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00390091 (ClinicalTrials.gov)	September 2006	17/10/2006	Study of LJP 394 (Abetimus Sodium) in Lupus Patients	A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetic and Pharmacodynamic Effects ...	Systemic Lupus Erythematosus	Drug: abetimus sodium (LJP 394)	La Jolla Pharmaceutical Company	NULL	Withdrawn	12 Years	70 Years	Both	0	Phase 2	United States
2	NCT00089804 (ClinicalTrials.gov)	October 2004	13/8/2004	Study of LJP 394 in Lupus Patients With History of Renal Disease	A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinationa ...	Lupus Erythematosus, Systemic;Lupus Nephritis	Drug: abetimus sodium (LJP 394)and/or placebo solution;Drug: abetimus sodium (LJP 394);Drug: Phospha ...	La Jolla Pharmaceutical Company	NULL	Terminated	12 Years	70 Years	Both	943	Phase 3	United States;Argentina;Australia;Belarus;Brazil;Bulgaria;Czech Republic;Georgia;Germany;Hong Kong;H ...
3	NCT00035308 (ClinicalTrials.gov)	November 2001	2/5/2002	Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in ...	Immunologic Diseases;Autoimmune Diseases;Systemic Lupus Erythematosus;Lupus Nephritis;Lupus Glomerul ...	Drug: Abetimus sodium (LJP 394)	La Jolla Pharmaceutical Company	NULL	Completed	12 Years	70 Years	Both	330	Phase 3	United States;Austria;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom

First Previous1Next Last